kabutan

TAUNS Laboratories,Inc.(197A) Summary

197A
TSE Standard
TAUNS Laboratories,Inc.
532
JPY
-1
(-0.19%)
Mar 13, 3:30 pm JST
3.33
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
535
Mar 13, 10:59 pm JST
Summary Chart Historical News Financial Result
PER
6.5
PBR
3.25
Yield
5.26%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
530 JPY 3.32 USD
Previous Close Mar 12
533 JPY 3.35 USD
High Mar 13, 10:34 am
534 JPY 3.35 USD
Low Mar 13, 9:03 am
528 JPY 3.31 USD
Volume
186,800
Trading Value
0.10B JPY 0.62M USD
VWAP
531.33 JPY 3.33 USD
Minimum Trading Value
53,200 JPY 333 USD
Market Cap
0.06T JPY 0.36B USD
Number of Trades
286
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
549
1-Year High Jul 15, 2025
1,982
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 129,900 1,862,000 14.33
Feb 27, 2026 112,700 2,122,700 18.83
Feb 20, 2026 107,300 2,238,200 20.86
Feb 13, 2026 133,300 2,356,600 17.68
Feb 6, 2026 125,600 2,438,300 19.41
Company Profile
TAUNS Laboratories, Inc. specializes in the development and manufacture of in vitro diagnostic medical devices and research reagents.
Sector
Pharmaceuticals
TAUNS Laboratories, Inc. focuses on the development and manufacture of in vitro diagnostic medical devices and research reagents as its core business, primarily offering antigen test kits for infectious disease clinical testing. By utilizing the immunochromatographic method, the company enables rapid diagnosis without the need for specialized equipment. Key features of their products include the common use of specimen extraction solution and high visibility black lines achieved through their proprietary "platinum-gold colloid" nanotechnology. The company provides its products to domestic and international medical institutions, international organizations, research institutes, and biotech ventures. Their main product line includes test kits for influenza, novel coronavirus, adenovirus, and RSV, among others.